Imatinib Mesylate Tablet, Film Coated
Product Images NDC 48433-049

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 48433-049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Safecor Health, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib Mesylate Structural Formula (Image 01)

Chemical structure diagram showing the molecular structure of imatinib, the active ingredient in Imatinib Mesylate tablets. The diagram includes rings and side chains consistent with the imatinib molecular formula.*

FDA Label Image

Progression Free Survival (itt Principle) (Image 02)

A Kaplan-Meier survival curve comparing the percentage of patients without progression over time between two treatment arms: imatinib and IFN+Ara-C. The X-axis shows months since randomization (0 to 72), and the Y-axis shows percentage without progression (0 to 100%). The chart includes patient numbers, hazard ratio with 95% confidence interval, and a log-rank test p-value.*

FDA Label Image

Time To Progression To Ap Or Bc (itt Principle) (Image 03)

A line graph depicting the percentage of patients without progression to AP/BC over time (months since randomization) for two groups: Imatinib arm (solid line) and IFN+Ara-C arm (dashed line). The graph includes patient counts, hazard ratio with confidence interval, and p-value comparing the two groups over a 72-month period.*

FDA Label Image

Study 1 Recurrence-free Survival (itt Population) (Image 04)

A Kaplan-Meier survival curve depicting the probability of being alive and recurrence-free over time in months, comparing Imatinib 400 mg with placebo. The graph shows survival probability on the vertical axis and survival time in months on the horizontal axis, with censored data points indicated for both groups. Patient numbers at risk are listed below the x-axis for multiple time points.*

FDA Label Image

Study 2 Recurrence-free Survival (itt Population) (Image 05)

A Kaplan-Meier survival curve chart showing the probability of recurrence-free survival over time in months for patients treated with Imatinib. The chart compares two groups: Imatinib 12 months and Imatinib 36 months, with censored observations marked. The x-axis represents survival time in months, and the y-axis shows the probability of recurrence-free survival in percentage. A hazard ratio and p-value are included in the figure.*

FDA Label Image

Study 2 Overall Survival (itt Population) (Image 06)

A Kaplan-Meier survival curve chart illustrating the probability of overall survival over time in months for two groups of Imatinib treatment durations (12 months and 36 months). The chart includes event markers, censored observations, p-value, hazard ratio with confidence interval, and at-risk event tables.*

FDA Label Image

Imatinib Mesylate Tablets 100 mg Unit Carton Label (Image 07)

Imatinib Mesylate 100 mg film-coated tablets oral dosage label by Safecor Health, LLC. The label shows two depictions of round, orange tablets embossed with '100'. The package contains 30 tablets (3 strips of 10). It includes storage instructions (20° to 25°C), manufacturer Mylan Pharmaceuticals Inc., Morgantown, WV, and indicates the product is made in Germany. Marked Rx only.*

FDA Label Image

Unit Carton (Image 08)

Packaging label for Imatinib Mesylate oral film-coated tablets by Safecor Health, LLC. The label features the UDL logo and states the product is for institutional use only, is not child-resistant, and highlights storage instructions. Contact information for Safecor Health is provided.*

FDA Label Image

Imatinib Mesylate Tablets 400 mg Unit Carton Label (Image 09)

Imatinib Mesylate 400 mg film-coated tablets label from Safecor Health, LLC. The label shows the product as oral tablets, packaged in a box of 30 tablets (3 x 10). It includes typical storage instructions, manufacturer's details (Mylan Pharmaceuticals Inc., Morgantown, WV), and notes for prescription use only. Images of the 400 mg tablet are also visible on the label.*

FDA Label Image

Unit Carton (Image 10)

Label panel for Imatinib Mesylate tablets by Safecor Health, LLC. It features the UDL logo and company information, usage warnings including non-child-resistant dose packaging and institutional use only, and storage instructions to keep out of children's reach and protect from light. Contact details and distribution location in Rockford, IL are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.